Impact Therap-b
7630.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.5B
Close$
$-2.81
122.9% downside
Current Fair Value
122.9% downsideOvervalued by 122.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.50 Billion |
|---|---|
| Enterprise Value | $3.38 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.15 |
| Beta | 0.23 |
| Outstanding Shares | 282,461,530 |
Return
| Return on Equity | -63.64% |
|---|---|
| Return on Assets | -42.75% |
| Return on Invested Capital | -38.07% |
Valuation & Multiples
| P/E Ratio | -12.23 |
|---|---|
| PEG | 49.03 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 164.17 |
| Enterprise Value to EBIT | -59.51 |
| Enterprise Value to Net Income | -47 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
$-0.04
Average shareholder expectationRevenue Estimate
$144.35 M
Average shareholder expectationNext Earnings Call
Expected Date
March 3, 2027
EPS Estimate
$-0.33
Average shareholder expectationRevenue Estimate
$187.14 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Impact Therap-b
88 employees
CEO: Sui-Xiong Cai IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and advancement of precision anti-cancer treatments rooted in synthetic lethality, operating across China and international markets. The company's primary offering, ...